enGene Therapeutics Warrants
ENGNW
15 hedge funds and large institutions have $3.7M invested in enGene Therapeutics Warrants in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
36.39% more ownership
Funds ownership: 9.34% → 45.73% (+36%)
27% more capital invested
Capital invested by funds: $2.91M → $3.7M (+$791K)
7% more funds holding
Funds holding: 14 → 15 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$70 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.58K |
ENGNW Hedge Fund Activity: Q2 2025 in Review
15 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q2 2025, worth a combined $3.7M — up 27% from $2.91M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ENGNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $70. The largest seller was UBS Group, cutting an estimated $1.58K.
- 15 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q2 2025, up from 14 in Q1 2025.
- Funds reported $3.7M of enGene Therapeutics Warrants stock for Q2 2025, up 27% quarter-over-quarter.
- 1 fund opened new enGene Therapeutics Warrants positions in Q2 2025 and 0 closed out, a net change of +1 holder.
- The largest enGene Therapeutics Warrants buyer in Q2 2025 was Toronto Dominion Bank, an estimated $70 added.
- The largest enGene Therapeutics Warrants seller in Q2 2025 was UBS Group, an estimated $1.58K sold.
Based on aggregated 13F filings for Q2 2025.